| Abstract | Ninety psoriasis patients, who were either completely cleared of or manifested only a minimal presence of disease signs following 3-4 weeks of twice daily treatment with augmented betamethasone dipropionate (ABD) ointment 0.05%, were enrolled in this multicenter, double-blind, placebo-controlled study. The study was designed to determine if an intermittent pulse dose regimen of ABD ointment could safely and effectively maintain a remission disease status when treatment was applied in three consecutive applications 12 h apart, once a week for a maximum treatment period of 6 months. The disease of 60% of the patients in the active treatment group was successfully controlled for 6 months, while 80% of the placebo-treated patients experienced exacerbation of disease signs. No serious local or systemic treatment-related adverse experiences were reported. ABD ointment 0.05%, when applied using the intermittent treatment regimen described here, was shown to be a clinically beneficial and well-tolerated method of long-term (up to 6 months) maintenance therapy for psoriasis patients. |
| Authors | H I Katz, S E Prawer, R S Medansky, G G Krueger, J J Mooney, M L Jones, C R Samson
(Affiliation: Minnesota Clinical Study Center, Fridley.)
|
| Journal | Dermatologica
(Dermatologica)
Vol. 183
Issue 4
Pg. 269-74
( 1991)
ISSN: 0011-9075 SWITZERLAND |
| PMID | 1809589
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
| Chemical References |
- Anti-Inflammatory Agents
- Ointments
- Betamethasone
- Hydrocortisone
- betamethasone-17,21-dipropionate
|
| Topics |
- Administration, Topical
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents
(administration & dosage, therapeutic use)
- Betamethasone
(administration & dosage, analogs & derivatives, therapeutic use)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Hydrocortisone
(blood)
- Male
- Middle Aged
- Ointments
- Psoriasis
(blood, drug therapy)
- Time Factors
|
